The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
The therapeutic monoclonal antibody market
Open accessAbstract
Since the commercialization of the first therapeutic monoclonal antibody product in 1986, this class of biopharmaceutical products has grown significantly so that, as of November 10, 2014, forty-seven monoclonal antibody products have been approved in the US or Europe for the treatment of a variety of diseases, and many of these products have also been approved for other global markets. At the current approval rate of ∼ four new products per year, ∼ 70 monoclonal antibody products will be on the market by 2020, and combined world-wide sales will be nearly $125 billion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Production of recombinant protein therapeutics in cultivated mammalian cells
Wurm, F. M. (2004) · Nature Biotechnology · doi:10.1038/nbt1026 · Cited by 2,032
Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs
DiMasi, J. A., Feldman, L., Seckler, A., & Wilson, A. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.295 · Cited by 845
Human Development Report 2013: The Rise of the South - Human Progress in a Diverse World
United Nations Development Programme (2013) · Human Development Report · doi:10.18356/a1b0c169-en · Cited by 704
Recombinant protein therapeutics—success rates, market trends and values to 2010
Pavlou, A. K., & Reichert, J. M. (2004) · Nature Biotechnology · doi:10.1038/nbt1204-1513 · Cited by 334
High-throughput process development for biopharmaceutical drug substances
Bhambure, R., Kumar, K., & Rathore, A. S. (2011) · Trends in Biotechnology · doi:10.1016/j.tibtech.2010.12.001 · Cited by 177
Perfusion seed cultures improve biopharmaceutical fed‐batch production capacity and product quality
Yang, W. C., Lü, J., Kwiatkowski, C., Yuan, H., Kshirsagar, R., Ryll, T., & Huang, Y. (2014) · Biotechnology Progress · doi:10.1002/btpr.1884 · Cited by 156
Liu, B., Spearman, M. A., Doering, J., Lattová, E., Perreault, H., & Butler, M. (2013) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2013.11.007 · Cited by 141
Lu, F., Toh, P. C., Burnett, I., Li, F., Hudson, T., Amanullah, A., & Li, J. (2012) · Biotechnology and Bioengineering · doi:10.1002/bit.24602 · Cited by 128
Rameez, S., Mostafa, S. S., Miller, C., et al. (2014) · Biotechnology Progress · doi:10.1002/btpr.1874 · Cited by 114
Povey, J. F., O'Malley, C. J., Root, T., Martin, E., Montague, G. A., Feary, M., Trim, C. M., Lang, D., Alldread, R. M., Racher, A. J., et al. (2014) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2014.04.028 · Cited by 59
Food and Drug Administration, Center for Drug Evaluation and Research
Jacobs, A., & Seifried, A. (2007) · Toxicologic Pathology · doi:10.1080/01926230701226575 · Cited by 44
Research works printed but not linked: 5
- Bioprocess Technology Consultants [Internet], 2014, bioTRAK® database
- Greb E, 2012, Pharmaceutical Technol, 36, 46
- Chollangi S, 2014, Bioprocess Int, 12, 48
- 10.12665/J124.Sha · doi:10.12665/j124.sha
- 10.2174/1566524053152898 · doi:10.2174/1566524053152898
Cited by
Aptamers as targeted therapeutics: current potential and challenges
Zhou, J., & Rossi, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.199 · Cited by 2,221
Development of therapeutic antibodies for the treatment of diseases
Lu, R.-M., Hwang, Y.-C., Liu, I.-J., Lee, C.-C., Tsai, H.-Z., Li, H.-J., & Wu, H.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0592-z · Cited by 2,085
Beyond binding: antibody effector functions in infectious diseases
Lu, L. L., Suscovich, T. J., Fortune, S. M., & Alter, G. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.106 · Cited by 825
Alternative molecular formats and therapeutic applications for bispecific antibodies
Spiess, C., Zhai, Q., & Carter, P. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.003 · Cited by 607
Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics
Bannas, P., Hambach, J., & Koch-Nolte, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01603 · Cited by 572
Metadata
- Authors
- Ecker, D. M., Jones, S. D., & Levine, H. L.
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2015-01-02
- Volume
- 7
- Issue
- 1
- Pages
- 9-14
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- OpenAlex
- W2094052190
- Cited by
- 1,286
- References
- 11
- FWCI
- 76.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.